What is PAQ Therapeutics?
PAQ Therapeutics is a pioneering biotechnology enterprise focused on harnessing the body's natural cellular degradation mechanism, known as autophagy. By utilizing its proprietary ATTEC (autophagosome-tethering compound) technology, the company is developing a novel class of small molecule degraders. These compounds are engineered to bind a diverse array of substrates—including proteins, lipids, organelles, and pathogens—to the autophagy pathway for efficient clearance. This approach represents a significant shift in therapeutic strategy, offering the potential to address previously undruggable targets and fundamentally transform the landscape of drug discovery and development for complex diseases.
How much funding has PAQ Therapeutics raised?
PAQ Therapeutics has raised a total of $69M across 2 funding rounds:
Series A
$30M
Series B
$39M
Series A (2021): $30M with participation from Huagai Capital, MSA Capital, Sherpa Healthcare Partners, and MRL Ventures Fund
Series B (2025): $39M led by BioTrack Capital, Johnson & Johnson Innovation, Bayland Capital Management, HealthSherpa, and MRL Ventures Fund
Key Investors in PAQ Therapeutics
MRL Ventures Fund
MRL Ventures Fund is a therapeutics-focused corporate venture group that partners with visionary founders to invest in early-stage, preclinical therapeutics companies globally, providing capital and strategic access to MSD's expertise.
Johnson & Johnson Innovation
Johnson & Johnson Innovation partners with entrepreneurs and early-stage businesses to develop healthcare solutions that improve lives globally, operating through a network of regional innovation centers.
BioTrack Capital
BioTrack Capital is a dedicated healthcare venture capital firm focused on building and incubating innovative life science companies, with a specific emphasis on discovering breakthrough biotech and medtech business models.
What's next for PAQ Therapeutics?
With the support of its latest investment, PAQ Therapeutics is poised to scale its research operations and advance its lead candidates toward critical development milestones. The company's strategic roadmap emphasizes the validation of its ATTEC platform across multiple therapeutic modalities, aiming to establish a robust pipeline of first-in-class degradation therapies. As the firm moves forward, the focus will likely shift toward expanding its intellectual property portfolio and fostering strategic collaborations with global pharmaceutical partners to translate its scientific breakthroughs into tangible patient outcomes. The current funding environment provides the necessary runway to navigate the complexities of preclinical development and prepare for future clinical trials.
See full PAQ Therapeutics company page
